Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2013-02-20
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-16 (study day 25.0); relationship: PROBABLE
severe
assessed
Severe APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-16 (study day 25.0); relationship: PROBABLE
moderate
assessed
Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-04 (study day 74.0); relationship: PROBABLE
severe
assessed
Severe PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-04 (study day 74.0); relationship: PROBABLE
Data queries
No data queries.